SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results and outlook are driving discussion: earnings and comparable sales beat expectations, but revenue missed, with the China restructuring weighing on reported sales, and shares declined. Bulls point to improving U.S. traffic and turnaround progress, while bears focus on the revenue miss, soft reported growth outlook and valuation.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Progress toward the Valaris merger including reported final Brazilian regulatory approvalhas renewed attention on RIG, with bullish traders citing the combined offshore fleet, contract backlog and elevated short interest as potential tailwinds. Others remain wary of share dilution, debt and the stocks muted reaction to positive developments; merger completion is still pending.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

MPC is drawing attention amid a powerful rally in refiners, with traders pointing to elevated crack spreads and tight refined-fuel supplies tied to geopolitical disruptions as support for refinery margins. The community is split between bullish momentum and expectations of a pullback, with some questioning whether unusually strong margins can last after the sectors sharp run.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is drawing attention amid a steep decline alongside other nuclear and small-modular-reactor stocks, with traders pointing to sector-wide weakness and questioning the valuation and commercialization prospects of a pre-revenue company. Some see the pullback as a buying opportunity tied to future AI data-center power demand, while others remain bearish on execution and dilution risks.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply in 2027 has fueled concern about pricing and revenue for CorMedixs flagship product, alongside the steep selloff. Traders are divided over whether DaVitas preliminary, company-specific modeling signals a lasting commercial headwind or overstates the risk given uncertainty around future reimbursement and product adoption.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is drawing attention as a proxy for private AI holdings, especially amid speculation about a potential Anthropic IPO. Bulls see the listing as a catalyst, while bears question the funds premium to NAV and point to dilution and claims that it reduced its Anthropic stake.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarins Q3 results marked its first profitable quarter in more than two years, while traders focused on its debt-free balance sheet and ongoing Barclays-led strategic review amid speculation about a sale or buyback. The discussion also weighs EMT2s missed primary progression endpoint against a favorable secondary overall-survival signal, with uncertainty about whether the cancer finding can be translated into regulatory or commercial value.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through North America and International Personal Care segments. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Dallas, TX.

Kimberly-Clark Corp.

Kimberly-Clark is drawing attention after preliminary Q3 results topped expectations and the company reaffirmed its outlook; traders also point to easing Huggies-related concerns in China and progress toward financing and regulatory approval for the Kenvue acquisition. Reactions are constructive around defensive-staples demand and the mergers potential, though some remain wary of deal execution and the stocks recent weakness.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high ahead of the expected Q3 report has focused attention on BRIUMVI sales and earnings expectations, alongside recurring, unconfirmed buyout speculation. Some traders attribute the rally to short-covering, while others caution that takeover rumors have repeatedly failed to materialize.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

AEHR is drawing attention for a sharp selloff amid concerns about its rich valuation, execution, and weakening price action. Traders are debating whether the decline is overdone ahead of earnings, with bulls pointing to AI chip-testing demand and expected growth while bears question whether orders and guidance will justify expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million.
Aligos Therapeutics (NASDAQ:ALGS) sharesread more...

Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock

Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and China Breakthrough Therapy designation.read more...

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal 

Equity

The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.read more...

This Micro Cap Biotech Stock Is Tracking Its Biggest Intraday Gains In 11 Months – Here’s Why A China Deal Has Retail Buzzing

Aligos Therapeutics announced a licensing deal with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B drug candidate in Greater China.

Aligos Therapeutics Earnings Report: Q4 Overview

A Peek at Aligos Therapeutics's Future Earnings

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Aligos Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Under the licensing deal signed earlier this year, Aligos granted Xiamen Amoytop Biotech exclusive rights to develop and sell its experimental hepatitis B treatment drug, pevifoscorvir sodium, in Greater China.</li><li>Under the deal, Aligos is eligible for up to $420 million in milestone payments tied to clinical, regulatory, and sales achievements.</li><li>Aligos Therapeutics had $54.9 million in cash, cash equivalents and short-term investments as of March 31, 2026.</li></ul> Shares of Aligos Therapeutics (ALGS) rose 21% in after-hours trading on Monday after the company announced it had received a $25-million upfront payment from its Chinese licensing partner.The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases. Aligos Therapeutics had only $54.9 million in cash, cash equivalents, and short-term investments as of March 31, 2026.<h2 class="st-heading-2">The Licensing Deal</h2>Under the licensing deal signed earlier this year, Aligos granted Xiamen Amoytop Biotech exclusive rights to develop and sell its experimental hepatitis B treatment, pevifoscorvir sodium, in Greater China. Aligos keeps full rights to the drug in the United States, Europe, Japan, South Korea, and all other markets.Under the deal, Aligos is eligible for up to $420 million in milestone payments tied to clinical, regulatory and sales achievements. It will also earn tiered royalties in the high single digits on net sales in the licensed region.The treatment has already received Breakthrough Therapy Designation from Chinese regulators, which can speed up the approval process. A joint steering committee between the two companies is now overseeing the program. As part of the broader collaboration, the partners also plan to start clinical testing in China of another Aligos drug candidate in the third quarter of this year.<h2 class="st-heading-2">How Did ALGS Retail Traders React?</h2>On Stocktwits, retail sentiment around ALGS stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user opined that the stock is highly undervalued.<stembedurl>https://www.stocktwits.com/saitek88/message/658388690</stembedurl>“Cash-in now, but the real read is whether this deal de-risks the story and adds validation for the asset. Market will watch follow-through on the platform, not just the headline,” another user wrote.<stembedurl>https://www.stocktwits.com/SmartCapitall/message/658384603</stembedurl><a href="https://stocktwits.com/symbol/ALGS">ALGS stock</a> has fallen by about 37% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivn-stock-drops-after-hours-on-potential-1.5-billion-offering/cZm1A9rR7lC">RIVN Stock Drops After-Hours On Potential $1.5B Offering Despite Upbeat Q2 Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Interactive Strength Inc. rose on Friday (Representative image: Getty Images)

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.80
Prev Close	$5.03
Open	$4.99
Dividend Yield	0.00%
50-Day Moving Average	$5.56
Beta	2.04
Avg. Volume	48,288.03
PE Ratio	-0.66

52-Week High	$13.69
52-Week Low	$3.98
Market Capitalization	$29.97M
EPS (Annual)	-$2.45
Price to Book	0.94
Revenue Per Employee	$26,658.54

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALGS Fundamentals